Concepedia

Mari McQuitty

MM

9

Publications

2.5K

Citations

9

H-Index

1997

Active since

Affiliations

Novartis (Switzerland)(Current)

Hôpital Saint-Louis

Université Paris Cité

Infectious Diseases and the Research Institute

Délégation Paris 7

Mari McQuitty is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1997–2015

9

Publications

9

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. · Blood · 2013 · 421 citations · Full text

Postoperative<i>Serratia marcescens</i>Wound Infections Traced to an Out‐of‐Hospital Source

Douglas J. Passaro, Lyn Waring, Robert W. Armstrong et al. · The Journal of Infectious Diseases · 1997 · 132 citations · Full text

Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid

John E. Conte, Jeffrey A. Golden, Mari McQuitty et al. · Antimicrobial Agents and Chemotherapy · 2002 · 63 citations · Full text

, , +13

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Mary Frances McMullin, Claire Harrison, Dietger Niederwieser et al. · Experimental Hematology and Oncology · 2015 · 41 citations · Full text

Rows per page

1–5 of 9